Wang Jianjun, Ruotsalainen Sanna, Moilanen Leena, Lepistö Päivi, Laakso Markku, Kuusisto Johanna
Department of Medicine, University of Kuopio, Kuopio University Hospital, PO Box 1777, FI-70211 Kuopio, Finland.
Eur Heart J. 2007 Apr;28(7):857-64. doi: 10.1093/eurheartj/ehl524. Epub 2007 Feb 15.
The metabolic syndrome (MetS) is defined as a clustering of cardiovascular risk factors characterized by insulin resistance. We investigated the relationship of the MetS and its single components, defined by all six different criteria, with coronary heart disease (CHD), cardiovascular disease (CVD), and all-cause mortality in a prospective population-based study.
The MetS was defined according to the World Health Organization (WHO), the European Group for the Study of Insulin Resistance (EGIR), the National Cholesterol Education Program (NCEP), the American College of Endocrinology (ACE), the International Diabetes Federation (IDF), and the American Heart Association (updated NCEP) criteria. We investgated the relationship of the MetS defined by aforementioned six criteria with CHD, CVD, and all-cause mortality with Cox regression analyses in a non-diabetic Finnish population of 1025 subjects, aged 65-74 years, during the 13-year follow-up. The MetS defined by all aforementioned criteria was associated with a statistically significant risk for CVD mortality when adjusted for all confounding variables (Hazards Ratios, HRs from 1.31 to 1.51). The MetS defined by the WHO, ACE, and IDF criteria was associated with an increased risk of CHD mortality (HRs from 1.42 to 1.58). There was no association between the MetS by any criteria and all-cause mortality. Of the single components of the MetS, the following predicted CVD mortality in multivariable models: impaired fasting glucose by the WHO, NCEP, and ACE criteria (HR 1.34) and by the IDF and updated NCEP criteria (HR 1.29); impaired glucose tolerance by the WHO and ACE criteria (HR 1.55); low HDL cholesterol by the EGIR criteria (HR 1.50) and by the NCEP, IDF, and updated NCEP criteria (HR 1.29); and microalbuminuria according to the WHO definition (HR 1.86).
The MetS defined by all six current criteria predicts CVD mortality in elderly subjects. However, of the single components of the MetS, IFG, IGT, low HDL cholesterol, and microalbuminuria predicted CVD mortality with equal or higher HRs when compared with the different definitions of the MetS. Therefore, our study suggests that the MetS is a marker of CVD risk, but not above and beyond the risk associated with its individual components.
代谢综合征(MetS)被定义为以胰岛素抵抗为特征的心血管危险因素聚集。在一项基于人群的前瞻性研究中,我们调查了由所有六种不同标准定义的代谢综合征及其单一成分与冠心病(CHD)、心血管疾病(CVD)和全因死亡率之间的关系。
代谢综合征根据世界卫生组织(WHO)、欧洲胰岛素抵抗研究组(EGIR)、美国国家胆固醇教育计划(NCEP)、美国内分泌学会(ACE)、国际糖尿病联盟(IDF)和美国心脏协会(更新后的NCEP)标准进行定义。在一项对1025名年龄在65 - 74岁的非糖尿病芬兰人群进行的为期13年的随访研究中,我们通过Cox回归分析研究了上述六种标准定义的代谢综合征与冠心病、心血管疾病和全因死亡率之间的关系。在对所有混杂变量进行校正后,上述所有标准定义的代谢综合征与心血管疾病死亡率的统计学显著风险相关(风险比,HRs从1.31到1.51)。由WHO、ACE和IDF标准定义的代谢综合征与冠心病死亡率增加相关(HRs从1.42到1.58)。任何标准定义的代谢综合征与全因死亡率之间均无关联。在代谢综合征的单一成分中,以下因素在多变量模型中预测心血管疾病死亡率:根据WHO、NCEP和ACE标准定义的空腹血糖受损(HR 1.34)以及根据IDF和更新后的NCEP标准定义的空腹血糖受损(HR 1.29);根据WHO和ACE标准定义的糖耐量受损(HR 1.55);根据EGIR标准定义的高密度脂蛋白胆固醇降低(HR 1.50)以及根据NCEP、IDF和更新后的NCEP标准定义的高密度脂蛋白胆固醇降低(HR 1.29);以及根据WHO定义的微量白蛋白尿(HR 1.86)。
所有六种现行标准定义的代谢综合征可预测老年人群的心血管疾病死亡率。然而,在代谢综合征的单一成分中,空腹血糖受损、糖耐量受损、高密度脂蛋白胆固醇降低和微量白蛋白尿在预测心血管疾病死亡率时,与代谢综合征的不同定义相比,具有相同或更高的HRs。因此,我们的研究表明,代谢综合征是心血管疾病风险的一个标志物,但并不高于与其各个成分相关的风险。